Dr Hecht joins company as first patient is enrolled in HTI phase I clinical trial AELIX Therapeutics, a drug development company specialized in the discovery and dev...

In patients with rheumatoid arthritis and suboptimal response to conventional synthetic disease-modifying antirheumatic drugs, the initiation of tocilizumab appears t...

miRagen Therapeutics has announced new interim results from its ongoing phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in pati...

Dimerix (ASX: DXB) is pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program. The Medical Advisory...

SGS today announced that it has entered into collaboration with Bavarian Nordic A/S, an international biotechnology company specialising in vaccines, to develop a new...

Pfizer says that its investigational, next-generation tyrosine kinase inhibitor lorlatinib showed clinically meaningful activity against lung tumors and brain metasta...

Exelixis’ liver cancer drug cabozantinib (Cabometyx) has met its primary end point in the global phase 3 Celestial trial.   Cabozantinib has achieved its primary...

Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-sever...

Clinerion announces that data integration to its Patient Recruitment System platform can now also process electronic medical records made available by hospitals using...

Ablynx has announced the establishment of Ablynx, Inc., its subsidiary in the USA, and the appointment of Mr Daniel Schneider as the General Manager to lead the comme...